國家衛生研究院 NHRI:Item 3990099045/13797
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 909075      Online Users : 888
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13797


    Title: The impact of urate-lowering therapy in post-myocardial infarction patients: Insights from a population-based, propensity score-matched analysis
    Authors: Tai, CJ;Wu, CC;Lee, KT;Tseng, TG;Wang, HC;Chang, FR;Yang, YH
    Contributors: National Institute of Cancer Research
    Abstract: The role of urate-lowering therapy (ULT) for the primary prevention of cardiovascular events has been widely discussed, but its evidence for the secondary prevention of myocardial infarction (MI) is limited. Therefore, we conduct a population-based, propensity score-matched cohort study to investigate the cardiovascular outcomes among post-MI patients with and without ULT. A total of 19,042 newly diagnosed in-hospital MI patients were selected using the Taiwan National Health Insurance Database between 1 January 2005 and 31 December 2016. After 1:1 propensity score matching with covariates, MI patients with (n=963) and without (n=963) ULT were selected for further analysis. The primary outcome was the all-cause mortality and the secondary outcomes were composite cardiovascular (CV) outcomes, including hospitalization for recurrent MI, stroke, heart failure, and cardiac arrhythmias. ULT users were associated with lower all-cause mortality (adjusted hazard ratio [adjHR], 0.67; 95% confidence interval [CI], 0.51-0.87) compared to the ULT nonusers. In addition, ULT users had a significantly lower risk of recurrent MI which needed revascularization by percutaneous coronary intervention or coronary artery bypass grafting (adjHR, 0.67; 95% CI, 0.53-0.86) than the ULT nonusers. The primary and secondary outcomes were not different between post-MI patients who received uricosuric agents and xanthine oxidase inhibitors. The anti-inflammatory effect of ULT plays an essential role in MI management. From a real-world setting, this study shows that ULT is associated with the lower risk of all-cause mortality in post-MI patients. In addition, the result shows the possible lower incidence of repeat revascularization procedures in the ULT users.
    Date: 2022-03
    Relation: Clinical Pharmacology and Therapeutics. 2022 Mar;111(3):655-663.
    Link to: http://dx.doi.org/10.1002/cpt.2473
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0009-9236&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000719365500001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85119085105
    Appears in Collections:[Yi-Hsin Yang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB34719019.pdf13645KbAdobe PDF220View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback